Gamma-aminobutyric acid type A receptor alpha-3 beta-2 gamma-2 subtype (GABA(A)R α3β2γ2)

The Gamma-aminobutyric acid type A (GABAA) receptor alpha-3 beta-2 gamma-2 subtype is a heteropentameric ligand-gated ion channel that serves as a primary mediator of fast inhibitory neurotransmission in the central nervous system [1, 6]. It is composed of two alpha-3, two beta-2, and one gamma-2 subunits, which together form a central pore selective for chloride ions [6, 8]. Upon binding of the neurotransmitter GABA, the receptor undergoes a conformational change that opens the channel, leading to chloride influx and hyperpolarization of the postsynaptic neuron [6, 10]. This specific subtype is highly expressed in the cerebral cortex, hippocampus, and spinal cord, where it plays a crucial role in modulating anxiety, muscle tone, and pain processing [1, 16]. Dysregulation of alpha-3-containing GABAA receptors is implicated in various neurological and psychiatric conditions, including generalized anxiety disorder, chronic pain syndromes, and epilepsy [6, 11, 16]. Pharmacologically, this receptor is a major target for benzodiazepines and other sedative-hypnotic drugs, which act as positive allosteric modulators to enhance GABA-induced currents [1, 5]. Selective modulation of the alpha-3 subunit is of significant therapeutic interest for developing anxiolytics and analgesics with reduced sedative side effects compared to non-selective GABAergic agents [16]. The receptor also interacts with various other classes of drugs, including barbiturates and general anesthetics, which bind to distinct allosteric sites to modulate channel activity [1, 9]. Understanding the precise stoichiometry and distribution of this subtype is essential for the design of next-generation neuropsychiatric treatments [6, 9].

Other names

GABAA receptor alpha3beta2gamma2GABRA3-GABRB2-GABRG2 complexAlpha-3 beta-2 gamma-2 GABAA receptor

Positive allosteric modulation, orthosteric agonism, and orthosteric antagonism